Evidence map›Paper›PMID 41191187›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Synthesis and in vitro characterization of [

Punita Bhardwaj, Caroline Frohner, Christopher Geppert, Christian Gorges, Winfried Brenner, Guilhem Claude, Sarah Spreckelmeyer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Punita BhardwajCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität Zu Berlin, Klinik Für Nuklearmedizin, Augustenburger Platz 1, 13353, Berlin, Germany.
Caroline FrohnerCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität Zu Berlin, Klinik Für Nuklearmedizin, Augustenburger Platz 1, 13353, Berlin, Germany.
Christopher GeppertForschungsreaktor TRIGA Mainz, Johannes-Gutenberg-Universität Mainz, Fritz-Strassmann-Weg 2, 55128, Mainz, Germany.
Christian GorgesForschungsreaktor TRIGA Mainz, Johannes-Gutenberg-Universität Mainz, Fritz-Strassmann-Weg 2, 55128, Mainz, Germany.
Winfried BrennerCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität Zu Berlin, Klinik Für Nuklearmedizin, Augustenburger Platz 1, 13353, Berlin, Germany.
Guilhem Claude *Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität Zu Berlin, Klinik Für Nuklearmedizin, Augustenburger Platz 1, 13353, Berlin, Germany.
Sarah Spreckelmeyer *Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität Zu Berlin, Klinik Für Nuklearmedizin, Augustenburger Platz 1, 13353, Berlin, Germany. sarah.spreckelmeyer@charite.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadiopharmaceuticals offer targeted treatment by combining diagnostic or therapeutic radionuclides with biologically active molecules. Auranofin is the only Food and Drug Administration (FDA) approved gold(I) complex, originally developed for the treatment of rheumatoid arthritis. Recent evidence has highlighted its potential as an anticancer agent due to its ability to disrupt redox signaling, inhibit thioredoxin reductase, and impair glycolytic metabolism. This study aims to incorporate the true theranostic radionuclide

resultsCarrier-added (c.a.)

conclusions[

Indexed as

198AuAuranofinCancer therapyGold(i) complexNuclear medicineRadiotheranosticsRedox metabolismSPECT imaging

Identifiers

PMID41191187
PMCPMC12589756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.